AMBITION: Establish value demonstration at the heart of development strategy and evidence generation

LABEL DRIVEN DEVELOPMENT

- Focus on regulatory needs (TPP)
- Focus on the conventional set of RCTs for registration
- RCT delivery an ongoing concern
- Assumes that modelling can address evidence gaps
- RWE* = post launch registry
- Value will be obvious to the experts

VALUE DRIVEN DEVELOPMENT

- Begins with "What are the unmet needs of patients and the healthcare system?"
- What evidence standards do different stakeholders require?
- Can RCTs address the unmet needs in terms of population and outcomes?
- What else needs to be done pre-launch alongside RCTs (PCT/ RLS, RWE, Models)?
- How soon can further evidence be delivered post launch (cross-country)?
- What trade-offs are possible to arrive at an optimal scenario (value and evidence required)?

*RWE = Real World Evidence



Target Value Proposition: Summary of the value story and key evidence claims that a new product would need to demonstrate to payers, policy makers, and prescribers (and at times, vaccinee); whether in the label; or built up from analysis of trials, RWE, patient outcomes research and modelling

For (Populations of interest)	[Target population] othe	cation, place in care pathway, er characteristics defining target group/s	
Who (need)	[Customer need]	Population/s of interest, defined in terms of Unmet Need: e.g. high risk factors or recent poor outcomes.	Summary statement of the nature of
Our product is / ambition	[Characterisation of Project]		the value delivered by the product: e.g. the first the best
	Prescribers	Patients	Payors
That will Deliver	Descriptive: stakeholder Oescriptive: additional value that will resonate with specific stakeholder	elements of strongly	onate strongly with all of the three

